ALNY Stock: Price, Earnings History and SEC Filings
Alnylam Pharmaceuticals, Inc. (ALNY) last traded at $165.00, down 5.17% on the latest session and down 33.1% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $15.72 against an analyst estimate of $1.46, a beat of 976.7%.
$165.00 -5.17%
1 month-33.13%
52-week high$479.79
52-week low$163.30
Volume7.06M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ALNY earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $15.72 | $1.46 | +976.71% |
| Jun 2026 | Jul 30, 2026 | $1.21 | $1.44 | -15.97% |
| Mar 2026 | Apr 30, 2026 | $1.51 | $0.91 | +65.93% |
| Dec 2025 | Feb 12, 2026 | $0.82 | $0.75 | +9.33% |
ALNY beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ALNY
SEC filing data is not available right now. You can search for ALNY on SEC EDGAR.
ALNY news
- 5 Best High Growth Stocks Outside Big TechOct 31, 2026 · finance.yahoo.com
- Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales ConcernsOct 31, 2026 · finance.yahoo.com
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysOct 30, 2026 · finance.yahoo.com
- Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS SaysOct 30, 2026 · finance.yahoo.com
- What Just Happened To Alnylam Stock?Oct 30, 2026 · trefis.com
- Alnylam Q3 Update Disappoints as TTR Revenue Trends Toward Low End, RBC SaysOct 30, 2026 · finance.yahoo.com
- Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and RocheOct 30, 2026 · finance.yahoo.com
- Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA DeliveryOct 30, 2026 · finance.yahoo.com
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is a US-listed public company on Nasdaq.